Oncternal Therapeutics (ONCT) shares tumbled 33% in recent Monday premarket activity after it said in a regulatory filing that Nasdaq believes the company is a "public shell" and will adopt more "stringent" criteria for its listing after its Nov. 14 announcement of workforce reduction.
Actuate Therapeutics (ACTU) stock fell 21%, extending Friday's loss.
Akoustis Technologies (AKTS) shares slipped 20%, continuing the previous session's loss.
Macy's (M) stock fell more than 3% after it reported preliminary fiscal Q3 results and said it was delaying its quarterly earnings release due to an "issue" it identified regarding delivery expenditures in one of its accrual accounts.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。